AbbVie price target raised to $261 from $249 at Guggenheim
Guggenheim raised the firm's price target on AbbVie to $261 from $249 and keeps a Buy rating on the shares. The firm updated its model ahead of the Q2 earnings report.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.